Pharmaceutical Technology on MSN
Arrowhead nets first commercial win as siRNA drug garners FDA approval
Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.
Arrowhead Pharmaceuticals (ARWR) has just gained FDA approval for REDEMPLO, its first-ever approved drug and the first siRNA therapy available for familial chylomicronemia syndrome. This regulatory ...
siRNA therapies show promise for treating diseases like cancer and genetic disorders, but their effectiveness depends on proper delivery. A recent study found that the method of mixing siRNA with ...
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
Phase 2 studies are ongoing to assess the efficacy and safety of ADX-038 in patients with complement-mediated diseases – SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx ...
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Sirius Therapeutics today announced that preliminary data from its Phase 1 clinical trial of SRSD107, a next generation siRNA therapeutic under clinical ...
The Board of Directors of CSPC Pharmaceutical Group announced it has received approval from China's National Medical Products Administration to begin clinical trials for SYH2061 Injection, an ...
Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback